These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 16604085)

  • 1. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor.
    Baral TN; Magez S; Stijlemans B; Conrath K; Vanhollebeke B; Pays E; Muyldermans S; De Baetselier P
    Nat Med; 2006 May; 12(5):580-4. PubMed ID: 16604085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein L-I is the trypanosome lytic factor of human serum.
    Vanhamme L; Paturiaux-Hanocq F; Poelvoorde P; Nolan DP; Lins L; Van Den Abbeele J; Pays A; Tebabi P; Van Xong H; Jacquet A; Moguilevsky N; Dieu M; Kane JP; De Baetselier P; Brasseur R; Pays E
    Nature; 2003 Mar; 422(6927):83-7. PubMed ID: 12621437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. African trypanosomes: intracellular trafficking of host defense molecules.
    Shiflett AM; Faulkner SD; Cotlin LF; Widener J; Stephens N; Hajduk SL
    J Eukaryot Microbiol; 2007; 54(1):18-21. PubMed ID: 17300512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The trypanosome lytic factor of human serum and the molecular basis of sleeping sickness.
    Vanhamme L; Pays E
    Int J Parasitol; 2004 Jul; 34(8):887-98. PubMed ID: 15217727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Human resistance to African trypanosoma infections].
    Perez-Morga D
    Bull Mem Acad R Med Belg; 2007; 162(7-9):381-6; discussion 386. PubMed ID: 18429487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The trypanolytic factor of human serum.
    Pays E; Vanhollebeke B; Vanhamme L; Paturiaux-Hanocq F; Nolan DP; Pérez-Morga D
    Nat Rev Microbiol; 2006 Jun; 4(6):477-86. PubMed ID: 16710327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics of resistance to the African trypanosomes. VI. Heredity of resistance and variable surface glycoprotein-specific immune responses.
    De Gee AL; Levine RF; Mansfield JM
    J Immunol; 1988 Jan; 140(1):283-8. PubMed ID: 3121739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydrodynamic gene delivery of baboon trypanosome lytic factor eliminates both animal and human-infective African trypanosomes.
    Thomson R; Molina-Portela P; Mott H; Carrington M; Raper J
    Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19509-14. PubMed ID: 19858474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutual self-defence: the trypanolytic factor story.
    Pays E; Vanhollebeke B
    Microbes Infect; 2008 Jul; 10(9):985-9. PubMed ID: 18675374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein L1 Variant Associated with Increased Susceptibility to Trypanosome Infection.
    Cuypers B; Lecordier L; Meehan CJ; Van den Broeck F; Imamura H; Büscher P; Dujardin JC; Laukens K; Schnaufer A; Dewar C; Lewis M; Balmer O; Azurago T; Kyei-Faried S; Ohene SA; Duah B; Homiah P; Mensah EK; Anleah F; Franco JR; Pays E; Deborggraeve S
    mBio; 2016 Apr; 7(2):e02198-15. PubMed ID: 27073096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The trypanolytic factor-mechanism, impacts and applications.
    Wheeler RJ
    Trends Parasitol; 2010 Sep; 26(9):457-64. PubMed ID: 20646962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody responses in resistant and susceptible inbred mice infected with Trypanosoma congolense.
    Mitchell LA; Pearson TW
    Immunology; 1986 Feb; 57(2):297-303. PubMed ID: 3949371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming resistance with designer immunotoxins.
    Braddock M
    Expert Opin Pharmacother; 2006 Jul; 7(10):1409-12. PubMed ID: 16805725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The human trypanolytic factor: a drug shaped naturally.
    Vanhamme L
    Infect Disord Drug Targets; 2010 Aug; 10(4):266-82. PubMed ID: 20429865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent regulation of B cell responses to surface and subsurface epitopes of African trypanosome variable surface glycoproteins.
    Reinitz DM; Mansfield JM
    J Immunol; 1988 Jul; 141(2):620-6. PubMed ID: 2454998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a tryptophan-like epitope borne by the variable surface glycoprotein (VSG) of African trypanosomes.
    Semballa S; Okomo-Assoumou MC; Holzmuller P; Büscher P; Magez S; Lemesre JL; Daulouede S; Courtois P; Geffard M; Vincendeau P
    Exp Parasitol; 2007 Feb; 115(2):173-80. PubMed ID: 17014849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-terminal mutants of apolipoprotein L-I efficiently kill both Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense.
    Lecordier L; Vanhollebeke B; Poelvoorde P; Tebabi P; Paturiaux-Hanocq F; Andris F; Lins L; Pays E
    PLoS Pathog; 2009 Dec; 5(12):e1000685. PubMed ID: 19997494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of human serum sensitivity in the context of T.B. rhodesiense sleeping sickness epidemiology and control.
    Rickman LR
    East Afr Med J; 1992 May; 69(5):272-8. PubMed ID: 1644047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular dialogue between African trypanosomes and humans].
    Pays E
    Bull Mem Acad R Med Belg; 2011; 166(10-12):358-63; discussion 364-5. PubMed ID: 23082501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human African trypanosomiasis with natural products (Review).
    Gehrig S; Efferth T
    Int J Mol Med; 2008 Oct; 22(4):411-9. PubMed ID: 18813846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.